Complement C4/C3 activation products and their receptors play important roles in linking innate with adaptive immunity. Two of these receptors, complement receptor type 1 (CR1/CD35) and type 2 (CR2/CD21), are members of a family of structurally related proteins called the Regulators of Complement Activation (RCA). CR2 and CR1 are expressed in mice on B lymphocytes, follicular dendritic cells and a small subset of T lymphocytes. Previous studies by ourselves and others using inhibitory monoclonal antibodies and gene targeted mice have demonstrated key roles for CR2 and CR1 in the development of humoral and cellular immunity as well as provided substantial evidence for a role in the maintenance of tolerance to certain self antigens. Another class of membrane RCA proteins also interacts with C4/C3 activation fragments, but rather than act as receptors, these molecules function as regulatory proteins to block inappropriate complement activation on self cells. In preliminary studies, we have shown that a model of renal ischemia-reperfusion injury is dependent upon alternative pathway complement activation that is initiated when one membrane RCA regulatory protein designated Crry changes its sub-cellular location away from the site of subsequent complement deposition. In addition, we have identified and characterized a novel role for the receptors CR2 and CR1 in the development of a pathogenic subset of natural antibodies that is critically important to the development of experimental intestinal ischemia-reperfusion injury. Finally, we have identified several novel genes with structural similarities to the RCA family and developed preliminary evidence that at least one of these can encode a complement binding and regulatory protein. We now propose to extend these studies by pursuing the following specific aims:
Specific Aim #1 : Identify the mechanisms by which the alternative pathway is activated in response to ischemia-reperfusion of the kidney and causes target organ injury.
Specific Aim #2 : Define the role of CR2/CR1 in the development of the pathogenic natural antibody repertoire that initiates intestinal ischemia-reperfusion injury.
Specific Aim #3 : Determine the functional activities and biologic relevance of novel SCR-containing candidate C3/C4 binding and regulatory proteins.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI031105-15
Application #
7410112
Study Section
Allergy and Immunology Study Section (ALY)
Program Officer
Esch, Thomas R
Project Start
1993-06-01
Project End
2011-04-30
Budget Start
2008-05-01
Budget End
2011-04-30
Support Year
15
Fiscal Year
2008
Total Cost
$333,030
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Asokan, Rengasamy; Banda, Nirmal K; Szakonyi, Gerda et al. (2013) Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). Mol Immunol 53:99-110
Elvington, Andrew; Atkinson, Carl; Kulik, Liudmila et al. (2012) Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J Immunol 188:1460-8
Thurman, Joshua M; Tchepeleva, Svetlana N; Haas, Mark et al. (2012) Complement alternative pathway activation in the autologous phase of nephrotoxic serum nephritis. Am J Physiol Renal Physiol 302:F1529-36
Renner, Brandon; Ferreira, Viviana P; Cortes, Claudio et al. (2011) Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int 80:165-73
Kulik, Liudmila; Chen, Kuan; Huber, Brigitte T et al. (2011) Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists. Mol Immunol 48:883-94
Renner, Brandon; Coleman, Kathrin; Goldberg, Ryan et al. (2010) The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol 185:3086-94
Renner, Brandon; Strassheim, Derek; Amura, Claudia R et al. (2010) B cell subsets contribute to renal injury and renal protection after ischemia/reperfusion. J Immunol 185:4393-400
Serkova, Natalie J; Renner, Brandon; Larsen, Brian A et al. (2010) Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice. Radiology 255:517-26
Kulik, Liudmila; Fleming, Sherry D; Moratz, Chantal et al. (2009) Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury. J Immunol 182:5363-73
Pappworth, Isabel Y; Kulik, Liudmila; Haluszczak, Catherine et al. (2009) Increased B cell deletion and significantly reduced auto-antibody titre due to premature expression of human complement receptor 2 (CR2, CD21). Mol Immunol 46:1042-9

Showing the most recent 10 out of 71 publications